中文摘要：

目的评价脂肪源间充质干细胞（AMSC）联合化疗治疗多发性骨髓瘤（MM）患者骨痛的疗效。方法治疗组10例MM患者，在接受M2方案化疗结束后48h，以每公斤体质量2×105个细胞剂量静脉输注无关供者AMSC；对照组给予M2方案化疗；以骨痛的缓解程度和血钙下降度作为评价指标。结果治疗组和对照组用药前均有骨痛，治疗2个周期后，治疗组完全缓解7例，部分缓解3例，有效率为100％；对照组完全缓解2例，部分缓解2例，有效率为40％，治疗组有效率高于对照组（P〈0．05）。治疗组血钙升高8例，治疗后均降至正常范围，下降率为100％；对照组血钙升高9例，治疗后4例降至正常范围，下降率为44．4％。治疗组患者在使用AMSC过程中均未见明显不良反应发生，患者耐受性良好。结论AMSC联合化疗可显著缓解多发性骨髓瘤患者的骨痛。

英文摘要：

Objective To study the therapeutic effect of adult adipose tissue-derived mesenchyreal stem cells （AMSC）combined with chemotherapy on bone pain in multiple myeloma patients. Methods In this randomized, controlled study, 20 patients with pathological osteolytic lesion induced by myeloma were enrolled. Patients were randomly divided into two groups. Ten cases in the treated group and the other 10 patients in the control group. Forty eight hours later after being treated with chemotherapy （M2）, a dose of 2× 105 AMSC per kilogram of the patients＇ weight were given intravenously in the treatment group. Patients in the control group were treated with chemotherapy （M2） only. Pain relief and the levels of serum calcium were observed. Results The effective rate of pain relief in treatment group and control group were 100% （treatment group） and 40% （control group）, respectively. All patients with hypercalcaemia（8/8） were corrected in the treatment group after two-cycle treatment, compared with 44. 4% （4/9） in the control group. Pain relief and the control of hypercalcaemia in the treatment group were superior to those in the control group. In addition, no AMSC infusion-related side-effects were observed in the treatment group. Conclusions Adult adipose tissue-derived mesenchymal stem cells combined with chemotherapy are effective in relieving bone pain in patients with multiple myeloma.